Axsome Therapeutics’ (AXSM) “Buy” Rating Reaffirmed at HC Wainwright
HC Wainwright restated their buy rating on shares of Axsome Therapeutics (NASDAQ:AXSM – Free Report) in a research report released on Tuesday, Marketbeat Ratings reports. HC Wainwright currently has a $180.00 price target on the stock. A number of other equities research analysts have also recently commented on AXSM. Cantor Fitzgerald restated an overweight rating […]
More Stories
Trump Heads to Alaska for Pivotal Summit With Putin on Ukraine War
By Emel Akan ANCHORAGE, Alaska—U.S. President Donald Trump departed Washington early on Aug. 15 for Alaska, where he will hold...
Citigroup Inc. Has $11.96 Million Stock Position in Illumina, Inc. (NASDAQ:ILMN)
Citigroup Inc. boosted its holdings in shares of Illumina, Inc. (NASDAQ:ILMN – Free Report) by 13.5% in the 1st quarter,...
Citigroup Inc. Reduces Holdings in Nutanix (NASDAQ:NTNX)
Citigroup Inc. lowered its position in shares of Nutanix (NASDAQ:NTNX – Free Report) by 4.4% during the first quarter, according...
Citigroup Inc. Has $12.47 Million Position in Enovis Corporation (NYSE:ENOV)
Citigroup Inc. lessened its holdings in shares of Enovis Corporation (NYSE:ENOV – Free Report) by 92.5% in the first quarter,...
Citigroup Inc. Grows Stake in Silvercorp Metals Inc. (NYSEAMERICAN:SVM)
Citigroup Inc. increased its stake in Silvercorp Metals Inc. (NYSEAMERICAN:SVM – Free Report) by 8,416.5% in the 1st quarter, HoldingsChannel...
Citigroup Inc. Buys 132,325 Shares of Kontoor Brands, Inc. (NYSE:KTB)
Citigroup Inc. raised its position in Kontoor Brands, Inc. (NYSE:KTB – Free Report) by 170.2% during the first quarter, according...